6/29/23, 12:43 AM RAPPORT Pathway Feedback Search Clinical Topics Home Studies RAPPORT RAPPORT Disease Disease Non-ST-elevation myocardial inf ST-elevation myocardial infarction Trial question What is the role of abciximab in patients with acute myocardial infarction of < 12 hours duration undergoing PCI in the pre-drug eluting stent era? Study design Multi-center Double blinded RCT Population Characteristics of study participants 28.0% female N = 483 72.0% male 483 patients (133 female, 350 male) Inclusion criteria: patients with acute myocardial infarction of < 12 hours duration undergoing PCI in the pre-drug eluting stent era Key exclusion criteria: severe thrombocytopenia, baseline PT > 1.2 times control, ongoing internal bleeding or recent major surgery, previous stroke, or severe uncontrolled hypertension Interventions N=241 abciximab (as a 0.25 mg/kg bolus followed by a 12-hour infusion of 0.125 g/kg/min, maximum, 10 g/min) N=242 placebo (matching placebo) https://web.pathway.md/studies/recz07io1cZZmVcaP 1/2 6/29/23, 12:43 AM RAPPORT Pathway Primary outcome Death, reinfarction, or urgent target vessel revascularization at 6 months 17.8 % 17.8 13.4 % 11.6 8.9 % Significant decrease 4.5 % NNT = 16 0.0 % Abciximab Placebo Significant decrease in death, reinfarction, or urgent target vessel revascularization at 6 months (11.6% vs. 17.8%; OR 0.61, 95% CI 0.36 to 1.02) Secondary outcomes No significant difference in death, reinfarction, or any target vessel revascularization at 6 months, by intention-to-treat analysis (28.2% vs. 28.1%; OR 1.01, 95% CI 0.68 to 1.5) Safety outcomes Significant differences in bleeding (16.6% vs. 9.5%, p = 0.02). Conclusion In patients with acute myocardial infarction of < 12 hours duration undergoing PCI in the pre-drug eluting stent era, abciximab was superior to placebo with respect to death, reinfarction, or urgent target vessel revascularization at 6 months. Reference Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998 Aug 25;98(8):734- 41. Open reference URL https://web.pathway.md/studies/recz07io1cZZmVcaP 2/2